These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 22342916)

  • 21. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
    Cooper CL; Davis HL; Angel JB; Morris ML; Elfer SM; Seguin I; Krieg AM; Cameron DW
    AIDS; 2005 Sep; 19(14):1473-9. PubMed ID: 16135900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine.
    Dupont J; Altclas J; Lepetic A; Lombardo M; Vázquez V; Salgueira C; Seigelchifer M; Arndtz N; Antunez E; von Eschen K; Janowicz Z
    Vaccine; 2006 Nov; 24(49-50):7167-74. PubMed ID: 16884836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.
    Li X; Yang X; Li L; Liu H; Liu J
    Vaccine; 2006 Apr; 24(16):3321-31. PubMed ID: 16472546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
    Lee AW; Vesikari T; Gilbert CL; Klopfer SO; Schödel FP; Bhuyan PK
    Vaccine; 2011 Oct; 29(45):7942-8. PubMed ID: 21875633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
    Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
    Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population.
    Jacques P; Moens G; Desombere I; Dewijngaert J; Leroux-Roels G; Wettendorff M; Thoelen S
    Vaccine; 2002 Nov; 20(31-32):3644-9. PubMed ID: 12399191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute hepatitis B caused by a vaccine-escape HBV strain in vaccinated subject: sequence analysis and therapeutic strategy.
    Luongo M; Critelli R; Grottola A; Gitto S; Bernabucci V; Bevini M; Vecchi C; Montagnani G; Villa E
    J Clin Virol; 2015 Jan; 62():89-91. PubMed ID: 25542480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Humoral immunity level and factors associated with the response to the vaccine against the hepatitis B virus in health personnel of the Case-Essalud National Hospital, Arequipa September 1995-March 2002].
    Campos Nizama J
    Rev Gastroenterol Peru; 2005; 25(2):141-9. PubMed ID: 16021199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B.
    Clark JR; Bartley K; Jepson CD; Craik V; March JB
    FEMS Immunol Med Microbiol; 2011 Mar; 61(2):197-204. PubMed ID: 21204995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization and immune effect of the hepatitis B-BCG combined vaccine for using a needle innoculation.
    Jin L; Wang G; Zhao X; Wang Z; Yang L; Yu A; Xu Y; Li W
    Vaccine; 2010 Aug; 28(37):6041-51. PubMed ID: 20619374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
    Li L; Tian YJ; Shen H; Zhao XP; Yang DL
    Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
    Cooper CL; Davis HL; Morris ML; Efler SM; Adhami MA; Krieg AM; Cameron DW; Heathcote J
    J Clin Immunol; 2004 Nov; 24(6):693-701. PubMed ID: 15622454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.
    Levie K; Gjorup I; Skinhøj P; Stoffel M
    Scand J Infect Dis; 2002; 34(8):610-4. PubMed ID: 12238579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses.
    Julier Z; de Titta A; Grimm AJ; Simeoni E; Swartz MA; Hubbell JA
    Vaccine; 2016 May; 34(21):2453-2459. PubMed ID: 27016652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.
    Halperin SA; Van Nest G; Smith B; Abtahi S; Whiley H; Eiden JJ
    Vaccine; 2003 Jun; 21(19-20):2461-7. PubMed ID: 12744879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines.
    Zuckerman JN; Zuckerman AJ; Symington I; Du W; Williams A; Dickson B; Young MD;
    Hepatology; 2001 Oct; 34(4 Pt 1):798-802. PubMed ID: 11584378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.
    Tielemans CL; Vlasak J; Kosa D; Billiouw JM; Verpooten GA; Mezei I; Ryba M; Peeters PC; Mat O; Jadoul MY; Polakovic V; Dhaene M; Treille S; Kuriyakose SO; Leyssen M; Houard SA; Surquin M
    Vaccine; 2011 Feb; 29(6):1159-66. PubMed ID: 21167859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.